Our Approach Has Created an Innovative Pipeline
in Targeted Radiopharmaceuticals

RYZ101 for Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Lung cancer is the second most common cancer in the United States with an estimated 238,440 new diagnoses per year, of which small cell lung cancer (SCLC) represents approximately 14%. Approximately two-thirds of patients with SCLC have metastatic disease at the time of diagnosis and approximately half of patients with SCLC overexpress SSTR2. We are evaluating RYZ101 in a Phase 1b clinical trial for extensive stage—SCLC in the first line treatment setting, in which  RYZ101 is being combined with current standard of care therapy.

Details of the study can be found on